August 30, 2021

By: douano@listlabs.com

List Labs currently has a GMP compliant version of HPT™ Lipopolysaccharide from Escherichia coli O113 in stock. What this means for you:

• You don’t need to buy an entire batch of lipopolysaccharide or wait months for production and release – Saves you valuable time
• Paying for as few as 50 vials of a proven product and purchasing as you need it, while supplies last, also saves you a tremendous amount of money
• Proven quality, product in use worldwide in clinical trials

Get to Phase one quickly with available GMP products

Time is money. The more time spent waiting for your materials to be manufactured is time that you are not conducting your clinical trials. Contracting a manufacturer to produce GMP products can take a year or more for manufacture and release, but with a GMP compliant product in stock, you can purchase what you need when you are ready.

Help your budget with available GMP products 

There are so many costs associated with research studies and clinical trials, who wouldn’t want to save a little money on their project? The expense of custom manufacturing can be steep – purchasing available GMP compliant products from List Labs can help alleviate some of those costs. Lipopolysaccharide is broadly used in many types of clinical trials such as in the study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer.¹

Lipopolysaccharide currently in use in clinical trials worldwide

List Labs’ GMP compliant version of HPT™ Lipopolysaccharide from Escherichia coli O113 has already been used by organizations around the world in clinical trials. The quality of this product is proven by the successful use in Phases one through three in past or ongoing clinical trials. This unique difference sets our GMP product apart from the competition and saves you the risk of an unknown product.

Contact us today to get your GMP LPS while there’s still product in stock!

See how List Labs’ products have been used in research projects on our citations page.

Reference

1. Dohnal AM, Witt V, Hügel H, Holter W, Gadner H, Felzmann T. Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy. 2007;9(8):755-70. Epub 2007 Oct 4. PMID: 17917887